Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AVANDAMET vs Metformin in T2DM
NCT00241605Phase 4Completed
- Sponsor
- GSK
- Start
- Jun 2003
- Primary completion
- Dec 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of rosiglitazone in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by GSK. Primary endpoint: Change from baseline in HbA1c at 48 weeks. Started Jun 2003; status: completed.
02
Drugs
rosiglitazone
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00241605.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00241605.